These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 1420919)
21. Small animal thrombosis models for the evaluation of thrombolytic agents. Stassen JM; Lijnen HR; Kieckens L; Collen D Circulation; 1991 Jun; 83(6 Suppl):IV65-72. PubMed ID: 2040073 [TBL] [Abstract][Full Text] [Related]
22. Peritoneal fibrinolysis: evidence for the efficiency of the tissue-type plasminogen activator. Moore KL; Bang NU; Broadie TA; Mattler LE; Marks CA J Lab Clin Med; 1983 Jun; 101(6):921-9. PubMed ID: 6682880 [TBL] [Abstract][Full Text] [Related]
23. Detection of thrombus formation on intravascular catheters using 125I-fibrinogen. O'Connell JP; Dunn TS; Rumaks A; Williams JL Thromb Res; 1981 Jan 1-15; 21(1-2):111-20. PubMed ID: 7233395 [No Abstract] [Full Text] [Related]
25. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946 [TBL] [Abstract][Full Text] [Related]
26. A comparative study of the inhibitors of fibrinolysis in human, dog and rabbit blood. Gallimore MJ; Nulkar MV; Shaw JT Thromb Diath Haemorrh; 1965 Sep; 14(1-2):145-58. PubMed ID: 16955972 [TBL] [Abstract][Full Text] [Related]
27. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma. Nielsen VG; Kirklin JK; George JF Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800 [TBL] [Abstract][Full Text] [Related]
28. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I. Terasawa F; Kani S; Hongo M; Okumura N Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498 [TBL] [Abstract][Full Text] [Related]
29. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Johansson AG; Løvdal T; Magnusson KE; Berg T; Skogh T Hepatology; 1996 Jul; 24(1):169-75. PubMed ID: 8707258 [TBL] [Abstract][Full Text] [Related]
30. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Konieczynska M; Fil K; Bazanek M; Undas A Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139 [TBL] [Abstract][Full Text] [Related]
31. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses. Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093 [TBL] [Abstract][Full Text] [Related]
32. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation. Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956 [TBL] [Abstract][Full Text] [Related]
33. A higher blood flow window of reduced thrombogenicity and acceptable fragmentation in a hollow fiber hemodialyzer. Dewanjee MK; Kapadvanjwala M; Mao WW; Jy W; Ahn Y; Ruzius K; Ghafouripour AK; Serafini AN; Sfakianakis GN ASAIO J; 1993; 39(3):M363-7. PubMed ID: 8268560 [TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. Collen D J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213 [TBL] [Abstract][Full Text] [Related]
35. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis. Colick JA; Fisher LM Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992 [No Abstract] [Full Text] [Related]
36. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro. Lourenço DM; Dosne AM; Kher A; Samama M Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812 [TBL] [Abstract][Full Text] [Related]
37. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890 [TBL] [Abstract][Full Text] [Related]
38. Fibrinogen, fibrin and crosslinking in aging arterial thrombi. McBane RD; Ford MA; Karnicki K; Stewart M; Owen WG Thromb Haemost; 2000 Jul; 84(1):83-7. PubMed ID: 10928475 [TBL] [Abstract][Full Text] [Related]
39. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Jones AJ; Meunier AM Thromb Haemost; 1990 Nov; 64(3):455-63. PubMed ID: 2128976 [TBL] [Abstract][Full Text] [Related]
40. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]